A new compound,
IGN-2098 [5,6-dimethyl-2-[4-<3-(1-piperidinomethyl) phenoxy>cis-butenylamino]-4-(1H)-
pyrimidone.2HCl], was found to be a potential
histamine H2-receptor antagonist in the guinea pig atrium.
IGN-2098, given p.o., significantly and persistently (for more than 12 hr) inhibited the basal gastric secretion in pylorus-ligated rats. The agent also significantly inhibited the basal gastric secretion when given by the s.c.-, i.d.- or i.p.-route. Stimulated gastric secretion in
fistula rats in response to
histamine,
carbachol or
pentagastrin was also significantly inhibited with
IGN-2098 given s.c. Pretreatment with
IGN-2098 (p.o.) significantly protected the gastric mucosa against pylorus
ligation-, water-immersion stress-,
histamine-,
indomethacin-, HCl.
aspirin-, and HCl.
ethanol-induced gastric lesions. In addition, the agent significantly protected the duodenal mucosa against
mepirizole-induced
ulcers. Based upon the ED50 values, the antisecretory effects on
histamine,
carbachol or
pentagastrin-stimulated
acid secretion were 6.0, 37.0 or 80 times more potent than
roxatidine, respectively. As to the anti-lesion effects on HCl.
aspirin-induced gastric lesions or
mepirizole-induced
duodenal ulcers,
IGN-2098 was 8.1 or 14.8 times more potent than
roxatidine, respectively. These results suggest that
IGN-2098 will be a useful
drug for the treatment of gastric and duodenal lesions in man.